Association between liver fibrosis and osteoporosis in adults aged 50 and older: insights from the Bushehr Elderly Health Program.

IF 1.6 Q4 ENDOCRINOLOGY & METABOLISM
Journal of Diabetes and Metabolic Disorders Pub Date : 2025-02-06 eCollection Date: 2025-06-01 DOI:10.1007/s40200-025-01574-z
Azin Soltani, Amirhossein Aghakhani, Hojat Dehghanbanadaki, Ziba Majidi, Mostafa Rezaei-Tavirani, Gita Shafiee, Afshin Ostovar, Seyed Amirhossein Mir Moeini, Fatemeh Bandarian, Bagher Larijani, Iraj Nabipour, Noushin Fahimfar, Farideh Razi
{"title":"Association between liver fibrosis and osteoporosis in adults aged 50 and older: insights from the Bushehr Elderly Health Program.","authors":"Azin Soltani, Amirhossein Aghakhani, Hojat Dehghanbanadaki, Ziba Majidi, Mostafa Rezaei-Tavirani, Gita Shafiee, Afshin Ostovar, Seyed Amirhossein Mir Moeini, Fatemeh Bandarian, Bagher Larijani, Iraj Nabipour, Noushin Fahimfar, Farideh Razi","doi":"10.1007/s40200-025-01574-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Both liver fibrosis and osteoporosis share inflammatory pathways, with liver fibrosis potentially contributing to decreased bone mineral density (BMD). The rising prevalence of non-alcoholic fatty liver disease (NAFLD) and associated liver fibrosis, especially in older populations, may increase the risk of osteoporosis, but evidence remains inconclusive. This study aims to investigate the relationship between liver fibrosis and osteoporosis in individuals over 50 years old.</p><p><strong>Methods: </strong>This cross-sectional study used data from the Bushehr Elderly Health Program (BEHP), a cohort of 2,000 participants aged 50 and older, selected through multistage stratified random sampling. BMD and trabecular bone score (TBS) measurements were assessed. The Fibrosis-4 (FIB-4) index, a surrogate marker for liver fibrosis, was also calculated to examine its association with these bone health indicators. Multiple linear regression was applied to assess the relationship between FIB-4 and lumbar, hip, femoral neck BMD, and TBS scores, while logistic regression was used to evaluate osteoporosis as the dependent variable.</p><p><strong>Results: </strong>A total of 1,959 participants with adequate data were included in our analysis. 538 participants had osteoporosis, 936 participants had osteopenia, and 485 participants had normal bone density. FIB-4 index was higher in osteoporotic groups (1.45 ± 0.90) than in osteopenic (1.26 ± 0.58, <i>p</i> < 0.001) and normal groups (1.17 ± 0.48, <i>p</i> < 0.001). After controlling for confounders, FIB-4 index was negatively associated with hip BMD (β<sub>men</sub>=-0.0162; 95% CI: -0.0313, -0.0012 and β<sub>women</sub>=-0.0221; 95% CI: -0.0340, -0.0102), femoral neck BMD (β<sub>men</sub>=-0.0216; 95% CI: -0.0356, -0.0076 and β<sub>women</sub>=-0.0233; 95% CI: -0.0342, 0.0124), and TBS (β<sub>men</sub>=-0.0154; 95% CI: -0.0264, -0.0043 and β<sub>women</sub>=-0.0244; 95% CI: -0.0338, -0.0149) in both genders and with lumbar BMD in women (β=-0.0176; 95% CI: -0.0307, -0.0045). An increase in the FIB-4 index was associated with more than a twofold rise in the risk of developing osteoporosis in women (OR = 2.123; 95% CI: 1.503, 3.000; <i>p</i> < 0.001) and a 36% higher risk in men (OR = 1.366; 95% CI: 1.012, 1.844; <i>p</i> = 0.042).</p><p><strong>Conclusions: </strong>Liver fibrosis is associated with decreased bone density and attenuated bone architecture. Elevated FIB-4 index has been identified as a risk factor for osteoporosis, indicating a potential link between liver fibrosis and deteriorating bone health.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"24 1","pages":"65"},"PeriodicalIF":1.6000,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11803014/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes and Metabolic Disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40200-025-01574-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Both liver fibrosis and osteoporosis share inflammatory pathways, with liver fibrosis potentially contributing to decreased bone mineral density (BMD). The rising prevalence of non-alcoholic fatty liver disease (NAFLD) and associated liver fibrosis, especially in older populations, may increase the risk of osteoporosis, but evidence remains inconclusive. This study aims to investigate the relationship between liver fibrosis and osteoporosis in individuals over 50 years old.

Methods: This cross-sectional study used data from the Bushehr Elderly Health Program (BEHP), a cohort of 2,000 participants aged 50 and older, selected through multistage stratified random sampling. BMD and trabecular bone score (TBS) measurements were assessed. The Fibrosis-4 (FIB-4) index, a surrogate marker for liver fibrosis, was also calculated to examine its association with these bone health indicators. Multiple linear regression was applied to assess the relationship between FIB-4 and lumbar, hip, femoral neck BMD, and TBS scores, while logistic regression was used to evaluate osteoporosis as the dependent variable.

Results: A total of 1,959 participants with adequate data were included in our analysis. 538 participants had osteoporosis, 936 participants had osteopenia, and 485 participants had normal bone density. FIB-4 index was higher in osteoporotic groups (1.45 ± 0.90) than in osteopenic (1.26 ± 0.58, p < 0.001) and normal groups (1.17 ± 0.48, p < 0.001). After controlling for confounders, FIB-4 index was negatively associated with hip BMD (βmen=-0.0162; 95% CI: -0.0313, -0.0012 and βwomen=-0.0221; 95% CI: -0.0340, -0.0102), femoral neck BMD (βmen=-0.0216; 95% CI: -0.0356, -0.0076 and βwomen=-0.0233; 95% CI: -0.0342, 0.0124), and TBS (βmen=-0.0154; 95% CI: -0.0264, -0.0043 and βwomen=-0.0244; 95% CI: -0.0338, -0.0149) in both genders and with lumbar BMD in women (β=-0.0176; 95% CI: -0.0307, -0.0045). An increase in the FIB-4 index was associated with more than a twofold rise in the risk of developing osteoporosis in women (OR = 2.123; 95% CI: 1.503, 3.000; p < 0.001) and a 36% higher risk in men (OR = 1.366; 95% CI: 1.012, 1.844; p = 0.042).

Conclusions: Liver fibrosis is associated with decreased bone density and attenuated bone architecture. Elevated FIB-4 index has been identified as a risk factor for osteoporosis, indicating a potential link between liver fibrosis and deteriorating bone health.

50岁及以上成人肝纤维化与骨质疏松症之间的关系:来自布什尔老年健康项目的见解
目的:肝纤维化和骨质疏松都有共同的炎症途径,肝纤维化可能导致骨密度(BMD)降低。非酒精性脂肪性肝病(NAFLD)和相关肝纤维化患病率的上升,特别是在老年人群中,可能会增加骨质疏松症的风险,但证据仍不确定。本研究旨在探讨50岁以上人群肝纤维化与骨质疏松症的关系。方法:本横断面研究采用多阶段分层随机抽样的方法,从布什尔老年人健康计划(BEHP)中选取2000名50岁及以上的参与者。评估骨密度和骨小梁评分(TBS)测量值。纤维化-4 (FIB-4)指数,肝纤维化的替代标志物,也被计算,以检查其与这些骨骼健康指标的关系。采用多元线性回归评估FIB-4与腰椎、髋关节、股骨颈BMD和TBS评分之间的关系,采用logistic回归评估骨质疏松症作为因变量。结果:共有1,959名有充分资料的参与者被纳入我们的分析。538名参与者患有骨质疏松症,936名参与者患有骨质减少症,485名参与者骨密度正常。骨质疏松组FIB-4指数(1.45±0.90)高于骨质减少组(1.26±0.58),p < p =-0.0162;95% CI: -0.0313, -0.0012, β女性=-0.0221;95% CI: -0.0340, -0.0102),股骨颈骨密度(β男性=-0.0216;95% CI: -0.0356, -0.0076, β女性=-0.0233;95% CI: -0.0342, 0.0124)和TBS (β男性=-0.0154;95% CI: -0.0264, -0.0043, β女性=-0.0244;95% CI: -0.0338, -0.0149),女性腰椎骨密度(β=-0.0176;95% ci: -0.0307, -0.0045)。FIB-4指数的增加与女性骨质疏松症发生风险增加两倍以上相关(OR = 2.123;95% ci: 1.503, 3.000;p = 0.042)。结论:肝纤维化与骨密度降低和骨结构减弱有关。FIB-4指数升高已被确定为骨质疏松症的危险因素,表明肝纤维化与骨骼健康恶化之间存在潜在联系。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Diabetes and Metabolic Disorders
Journal of Diabetes and Metabolic Disorders Medicine-Internal Medicine
CiteScore
4.80
自引率
3.60%
发文量
210
期刊介绍: Journal of Diabetes & Metabolic Disorders is a peer reviewed journal which publishes original clinical and translational articles and reviews in the field of endocrinology and provides a forum of debate of the highest quality on these issues. Topics of interest include, but are not limited to, diabetes, lipid disorders, metabolic disorders, osteoporosis, interdisciplinary practices in endocrinology, cardiovascular and metabolic risk, aging research, obesity, traditional medicine, pychosomatic research, behavioral medicine, ethics and evidence-based practices.As of Jan 2018 the journal is published by Springer as a hybrid journal with no article processing charges. All articles published before 2018 are available free of charge on springerlink.Unofficial 2017 2-year Impact Factor: 1.816.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信